UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Wnt/beta-catenin pathway: modulating anticancer immune response

Journal of hematology and oncology, 2017-05, Vol.10 (1), p.101-101, Article 101

2017

Volltextzugriff (PDF)

Targeting Epidermal Growth Factor Receptor in triple negative breast cancer: New discoveries and practical insights for drug development

Cancer treatment reviews, 2017-02, Vol.53, p.111-119

2017

Volltextzugriff (PDF)

Variant graph craft (VGC): a comprehensive tool for analyzing genetic variation and identifying disease-causing variants

BMC bioinformatics, 2024-09, Vol.25 (1), p.1-14, Article 288

2024

Volltextzugriff (PDF)

Camonsertib in DNA damage response-deficient advanced solid tumors: phase 1 trial results

Nature medicine, 2023-06, Vol.29 (6), p.1400-1411

2023

Volltextzugriff (PDF)

Emerging therapeutic targets in bladder cancer

Cancer treatment reviews, 2015-02, Vol.41 (2), p.170-178

2015

Volltextzugriff (PDF)

Therapeutic targeting of TRAIL death receptors

Biochemical Society transactions, 2023-02, Vol.51 (1), p.57-70

2023

Volltextzugriff (PDF)

Concordance between genomic alterations assessed by next-generation sequencing in tumor tissue or circulating cell-free DNA

Oncotarget, 2016-10, Vol.7 (40), p.65364-65373

2016

Volltextzugriff (PDF)

Adenoid cystic carcinoma: current therapy and potential therapeutic advances based on genomic profiling

Oncotarget, 2015-11, Vol.6 (35), p.37117-37134

2015

Volltextzugriff (PDF)

Genomic characterization of high-risk non-muscle invasive bladder cancer

Oncotarget, 2016-11, Vol.7 (46), p.75176-75184

2016

Volltextzugriff (PDF)

Clinical activity of 9-ING-41, a small molecule selective glycogen synthase kinase-3 beta (GSK-3β) inhibitor, in refractory adult T-Cell leukemia/lymphoma

Cancer biology & therapy, 2022-12, Vol.23 (1), p.417-423

2022

Volltextzugriff (PDF)

BRCA1/2 Reversion Mutations in Patients Treated with Poly ADP-Ribose Polymerase (PARP) Inhibitors or Platinum Agents

Medicina (Kaunas, Lithuania), 2022-12, Vol.58 (12), p.1818

2022

Volltextzugriff (PDF)

Nodal Signaling as a Developmental Therapeutics Target in Oncology

Molecular cancer therapeutics, 2017-05, Vol.16 (5), p.787-792

2017

Volltextzugriff (PDF)

Anaplastic Lymphoma Kinase Mutation ( ALK F1174C) in Small Cell Carcinoma of the Prostate and Molecular Response to Alectinib

Clinical cancer research, 2018-06, Vol.24 (12), p.2732-2739

2018

Volltextzugriff (PDF)

Systematic review and meta-analysis of selected toxicities of approved ALK inhibitors in metastatic non-small cell lung cancer

Oncotarget, 2018-04, Vol.9 (31), p.22137-22146

2018

Volltextzugriff (PDF)

Strategies to sensitize cancer cells to immunotherapy

Human vaccines & immunotherapeutics, 2021-08, Vol.17 (8), p.2595-2601

2021

Volltextzugriff (PDF)

Glycogen Synthase Kinase-3 Beta Expression Correlates With Worse Overall Survival in Non-Small Cell Lung Cancer-A Clinicopathological Series

Frontiers in oncology, 2021-03, Vol.11, p.621050-621050

2021

Volltextzugriff (PDF)

Targeting mTOR signaling pathways and related negative feedback loops for the treatment of acute myeloid leukemia

Cancer biology & therapy, 2015-01, Vol.16 (5), p.648-656

2015

Volltextzugriff (PDF)

Phase 1/2 study of monalizumab plus durvalumab in patients with advanced solid tumors

Journal for immunotherapy of cancer, 2024-02, Vol.12 (2), p.e007340

2024

Volltextzugriff (PDF)

Commentary: GSK-3 Inhibition as a Therapeutic Approach Against SARs CoV2: Dual Benefit of Inhibiting Viral Replication While Potentiating the Immune Response

Frontiers in immunology, 2020-10, Vol.11, p.595289-595289

2020

Volltextzugriff (PDF)

Developmental therapeutics for inflammatory breast cancer: Biology and translational directions

Oncotarget, 2017-02, Vol.8 (7), p.12417-12432

2017

Volltextzugriff (PDF)

p53 Expression, Programmed Death Ligand 1, and Risk Factors in Urinary Tract Small Cell Carcinoma

Frontiers in oncology, 2021-04, Vol.11, p.651754-651754

2021

Volltextzugriff (PDF)

Tyrosine kinase inhibitor therapy in chronic myeloid leukemia: update on key adverse events

Expert review of hematology, 2015-08, Vol.8 (4), p.457-479

2015

Volltextzugriff (PDF)

FGFR3–TACC3: A novel gene fusion in cervical cancer

Gynecologic oncology reports, 2015-08, Vol.13 (C), p.53-56

2015

Volltextzugriff (PDF)

Glycogen synthase kinase-3 beta inhibitors as novel cancer treatments and modulators of antitumor immune responses

Cancer biology & therapy, 2019-08, Vol.20 (8), p.1047-1056

2019

Volltextzugriff (PDF)

Molecular Pathways: Revisiting Glycogen Synthase Kinase-3β as a Target for the Treatment of Cancer

Clinical cancer research, 2017-04, Vol.23 (8), p.1891-1897

2017

Volltextzugriff (PDF)

1 – 25 von 411

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(346)
Mit Volltextzugriff
(348)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(153)
Life Sciences & Biomedicine
(135)
Humans
(76)
Oncology
(65)
Forestry
(33)
Male
(32)
Female
(29)
Tumors
(21)
Cancer
(19)
Immunotherapy
(19)
Mutation
(19)
Review
(19)
Technology
(18)
Animals
(17)
Cell Biology
(16)
Patients
(16)
Adult
(13)
Metastasis
(13)
Middle Aged
(13)
Antineoplastic Agents - Therapeutic Use
(12)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(3)
... seit 90 Tagen
(8)

Menü

Weitere Dienste

Einstellungen

Wnt/beta-catenin pathway: modulating anticancer immune response

Targeting Epidermal Growth Factor Receptor in triple negative breast cancer: New discoveries and practical insights for drug development

Variant graph craft (VGC): a comprehensive tool for analyzing genetic variation and identifying disease-causing variants

Camonsertib in DNA damage response-deficient advanced solid tumors: phase 1 trial results

Emerging therapeutic targets in bladder cancer

Therapeutic targeting of TRAIL death receptors

Concordance between genomic alterations assessed by next-generation sequencing in tumor tissue or circulating cell-free DNA

Adenoid cystic carcinoma: current therapy and potential therapeutic advances based on genomic profiling

Genomic characterization of high-risk non-muscle invasive bladder cancer

Clinical activity of 9-ING-41, a small molecule selective glycogen synthase kinase-3 beta (GSK-3β) inhibitor, in refractory adult T-Cell leukemia/lymphoma

BRCA1/2 Reversion Mutations in Patients Treated with Poly ADP-Ribose Polymerase (PARP) Inhibitors or Platinum Agents

Nodal Signaling as a Developmental Therapeutics Target in Oncology

Anaplastic Lymphoma Kinase Mutation ( ALK F1174C) in Small Cell Carcinoma of the Prostate and Molecular Response to Alectinib

Systematic review and meta-analysis of selected toxicities of approved ALK inhibitors in metastatic non-small cell lung cancer

Strategies to sensitize cancer cells to immunotherapy

Glycogen Synthase Kinase-3 Beta Expression Correlates With Worse Overall Survival in Non-Small Cell Lung Cancer-A Clinicopathological Series

Targeting mTOR signaling pathways and related negative feedback loops for the treatment of acute myeloid leukemia

Phase 1/2 study of monalizumab plus durvalumab in patients with advanced solid tumors

Commentary: GSK-3 Inhibition as a Therapeutic Approach Against SARs CoV2: Dual Benefit of Inhibiting Viral Replication While Potentiating the Immune Response

Developmental therapeutics for inflammatory breast cancer: Biology and translational directions

p53 Expression, Programmed Death Ligand 1, and Risk Factors in Urinary Tract Small Cell Carcinoma

Tyrosine kinase inhibitor therapy in chronic myeloid leukemia: update on key adverse events

FGFR3–TACC3: A novel gene fusion in cervical cancer

Glycogen synthase kinase-3 beta inhibitors as novel cancer treatments and modulators of antitumor immune responses

Molecular Pathways: Revisiting Glycogen Synthase Kinase-3β as a Target for the Treatment of Cancer

Suchergebnisse filtern